Side-effect free RNA therapeutics active only in diseased cells

SRTD biotech secures seed financing

18-Nov-2024 - Jülich-based biotech start-up SRTD biotech GmbH has successfully closed a seven-figure seed financing round. The company will use the fresh capital to accelerate the development of novel RNA therapeutics. Based on a proprietary platform technology, SRTD biotech aims to develop highly efficient ...

Generative AI antibody design platform

Antiverse raises £3.5M

21-Oct-2024 - Antiverse, a techbio company designing antibodies for challenging targets, announced it has added £3.5M ($4.6M) to its seed funding. The investment will facilitate the Company’s growth, including appointments to strengthen the team and continued development of its antibody design programmes, many ...

Don’t kill the messenger RNA!

First mRNA stabilizing substance could open new ways in the development of innovative mRNA therapeutic

18-Oct-2024 - mRNA-based therapeutics and vaccines are the new hope in the fight against incurable diseases. A commonly used strategy in the development of messenger RNA (mRNA) medicine is based on the destruction of disease-causing mRNA. Achieving the opposite and stabilizing health-promoting mRNA is still a ...

ImmunOs Therapeutics raises $11 million and further strengthens investor base

“ImmunOs Therapeutics has a very innovative approach to target myeloid checkpoints which are potentially the next major breakthrough in immuno-oncology”

24-Sep-2024 - ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its unique immune system modulating HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, announced the closing of a Series C financing round of $11 million. The ...

Efficiency boost for drug discovery

Insilico Medicine and Inimmune achieved collaboration to revolutionize immunotherapy with AI-driven drug discovery

12-Sep-2024 - Insilico Medicine announced that the company has achieved a groundbreaking collaboration with Inimmune, which will utilize Chemistry42, Insilico's proprietary generative artificial intelligence (AI) technology to accelerate the discovery and development of next-generation ...

Researchers discover an alternative to PEG

rPEG as a new type of Poly(ethylene glycol): random chains offer multiple advantages for medical application

28-Jun-2024 - Researchers have discovered a highly promising replacement for polyethylene glycols (or PEGs), which are considered almost indispensable in the pharmaceutical and medical fields. The new substance class called rPEG offers all the advantages of PEGs, while avoiding their drawbacks and has the ...

LMU research transfer: several start-ups attract 7-figure investments

In successful funding rounds, three LMU spin-offs have brought in investments worth millions.

25-Jun-2024 - Tubulis, Smart Reporting, and Eisbach Bio have successfully attracted new investor funding. The new capital will enable the companies, for example, to expand their research and development activities. Tubulis and Eisbach develop new therapeutic approaches and active agents for cancer treatment, ...

Novel cancer therapeutic with components from basic research enters clinical phase

"I am excited by the progress the Tubulis team has made over the last few years toward this major milestone"

24-Jun-2024 - Groundbreaking innovations by researchers at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) provided the basis for the development of an antibody-drug conjugate (ADC) by the company Tubulis, which is now being used in a Phase I/IIa trial in tumour patients. Thanks to an ...

Biotechnology start-up using AI to translate nature into new medicines

Enveda Biosciences announces $55M in new funding to accelerate platform and advance multiple candidates to clinical trials

19-Jun-2024 - Enveda Biosciences announced a new financing round of $55 million to add to its $119 million combined Series B and B1. New investors Premji Invest, Lingotto Investment Fund, Microsoft, and The Nature Conservancy participated in the round alongside existing investors Kinnevik, True Ventures, FPV, ...

Tacalyx Extends Seed Round to over €14 M to Advance Development of its Cancer Therapeutics Targeting TACAs

17-Jun-2024 - Tacalyx, a privately held biotech company focused on developing novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, announces the extension of its seed financing to over €14 M. This extension round was led by new investor Thuja Capital, and as part of the financing, Evan ...